Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02357433
Other study ID # 01-2015_R
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date February 2015
Est. completion date June 2018

Study information

Verified date July 2018
Source Hospital Universitario San Juan de Alicante
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study objective is to clarify whether the application of high doses CPFA (Coupled Plasma-Filtration Adsorption) in addition to the current clinical practice is able to reduce hospital mortality in septic shock patients in intensive care unit (ICU).


Recruitment information / eligibility

Status Terminated
Enrollment 55
Est. completion date June 2018
Est. primary completion date June 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- all patients admitted to the ICU in septic shock

- all patients that develop septic shock while in the ICU

Exclusion Criteria:

- Age less than 18 years

- Pregnancy

- Estimated life expectancy (due to comorbidities) less than 90 days

- Presence of relative or absolute contraindications to CPFA

- Absence of informed consen

Study Design


Related Conditions & MeSH terms


Intervention

Device:
High Doses CPFA


Locations

Country Name City State
Spain Hospital General Universitario de Alicante Alicante
Spain Hospital General Universitario de Santa Lucia Cartagena Murcia
Spain Hospital de Vinalopó Elche Alicante
Spain Hospital Frances De Borja de Gandia Gandia Valencia
Spain Hospital de la Vega Baja Orihuela Alicante
Spain Hospital Universitario de San Juan de Alicante Sant Joan d'Alacant Alicante
Spain Hospital de Torrevieja Torrevieja Alicante
Spain Hospital Marina Baixa Villajoyosa Alicante
Spain Hospital de la Plana Villarreal Castellon
Spain Hospital Lluis Alcanyis Xátiva Valencia

Sponsors (1)

Lead Sponsor Collaborator
Francisco Colomina Climent

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Hospital mortality 28 days
Secondary time resolution of septic shock normalization of lactate, and the decrease in vasoactive drugs within the first 28 days
See also
  Status Clinical Trial Phase
Recruiting NCT03649633 - Vitamin C, Steroids, and Thiamine, and Cerebral Autoregulation and Functional Outcome in Septic Shock Phase 1/Phase 2
Terminated NCT04117568 - The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Completed NCT05629780 - Temporal Changes of Lactate in CLASSIC Patients N/A
Recruiting NCT04796636 - High-dose Intravenous Vitamin C in Patients With Septic Shock Phase 1
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Recruiting NCT05217836 - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Recruiting NCT05066256 - LV Diastolic Function vs IVC Diameter Variation as Predictor of Fluid Responsiveness in Shock N/A
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3
Not yet recruiting NCT04516395 - Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae N/A
Recruiting NCT02899143 - Short-course Antimicrobial Therapy in Sepsis Phase 2
Recruiting NCT02580240 - Administration of Hydrocortisone for the Treatment of Septic Shock N/A
Recruiting NCT02565251 - Volemic Resuscitation in Sepsis and Septic Shock N/A
Recruiting NCT02676427 - Fluid Responsiveness in Septic Shock Evaluated by Caval Ultrasound Doppler Examination
Completed NCT02638545 - Hemodynamic Effects of Dexmedetomidine in Septic Shock Phase 3
Terminated NCT02335723 - ASSET - a Double-Blind, Randomized Placebo-Controlled Clinical Investigation With Alteco® LPS Adsorber N/A
Not yet recruiting NCT02547467 - TOADS Study: TO Assess Death From Septic Shock. N/A
Completed NCT02079402 - Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care Phase 4
Completed NCT02306928 - PK Analysis of Piperacillin in Septic Shock Patients N/A